Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 15/20 | 0.50 |
| ▸ | EGLN2 | Q96KS0 | 6/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17629646 | 0.88 | KDM4E (0.49) | EGLN1EGLN2EGLN3KDM4EALDH1A1 | |
| SCHEMBL17629620 | 0.88 | KDM4E (0.52) | EGLN1EGLN2EGLN3KDM4EALDH1A1 | |
| SCHEMBL17629417 | 0.83 | PKM (0.43) | EGLN1EGLN2EGLN3KDM4EALDH1A1 | |
| SCHEMBL974330 | 0.81 | PKM (0.47) | EGLN1KDM4EALDH1A1TSHRNPC1 | |
| SCHEMBL19227012 | 0.80 | PKM (0.41) | EGLN1KDM4EALDH1A1TSHRNPC1 | |
| SCHEMBL17640901 | 0.79 | PKM (0.45) | EGLN1KDM4EALDH1A1TSHRNPC1 | |
| SCHEMBL17633307 | 0.74 | EGLN1 (0.36) | EGLN1EGLN2EGLN3CYSLTR2 | |
| SCHEMBL19251706 | 0.74 | EGLN1 (0.52) | EGLN1KDM4EALDH1A1TSHRNPC1 | |
| SCHEMBL17633173 | 0.73 | EGLN1 (0.36) | EGLN1EGLN2EGLN3CYSLTR2 | |
| SCHEMBL17629650 | 0.73 | PKM (0.46) | EGLN1EGLN2EGLN3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197452-B1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10208060-B2 | Inhibitors of HIF prolyl hydroxylase | MERCK SHARP & DOHME CORP. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170313718-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170226120-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-10 | — | — | US | disclosed |
| EP-3197452-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | Merck Sharp & Dohme Corp. (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197451-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | Merck Sharp & Dohme Corp. (US) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016049100-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016049098-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016049098-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313718-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | HIF1AN, EGLN2, EGLN3 | EGLN1 6/4885EGLN2 2/4885EGLN3 3/4885 |
| US-20170226120-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN1 6/4885EGLN2 3/4885EGLN3 4/4885 |
| US-10208060-B2 | Inhibitors of HIF prolyl hydroxylase | HIF1AN, EGLN2, EGLN3 | EGLN1 6/4885EGLN2 2/4885EGLN3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.